Connect with us

Health

BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity – NewsMaker

BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity

Published

on

Vancouver, BC, Nov 2, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2,…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending